Pimecrolimus

This classification denotes an immunosuppressant with the molecular formula C43H68ClNO11, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 7KYV510875, chemically known as 15,19-epoxy-3h-pyrido(2,1-c)(1,4)oxaazacyclotricosine-1,7,20,21(4h,23h)-tetrone, 3-(2-(4-chloro-3-methoxycyclohexyl)-1-methylethenyl)-8-ethyl-, 5,6,8,11,12,13,14,15,16,17,18,19,24,25,26,26a-hexadecahydro-5,19-dihydroxy-14,16-dimethoxy-4,10,12,18-tetramethyl-, (3s-(3r*(e(1s*,3s*,4r*)),4s*,5r*,8s*,9e,12r*,14r*,15s*,16r*,18s*,19s*,26ar*))- but more generally known as pimecrolimus, which bears US NIH Compound Identifier 6447131. European Medicines Agency schedules Pimecrolimus in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB16457MIG. The term PIMECROLIMUS is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 14, No. 1, 2000, List 43). World Health Organization schedules pimecrolimus in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations, for tariff and trade purposes, schedule pimecrolimus under HS 29349990 and SITC 51579. As of Q4 2014, PIMECROLIMUS remains US FDA's Preferred Term for this commodity. Pimecrolimus bears US NLM identifiers UMLS ID C1099414 and NCI Concept Code C47671. SMILES: CLC1C(OC)CC(CC1)/C=C(/C1OC(=O)C2N(C(=O)C(=O)C3(OC(C(OC)CC3C)C(OC)CC(CC(=CC(C(=O)CC(O)C1C)CC)C)C)O)CCCC2)C.